Which is the treatment of choice for a hemodynamically stable patient with paroxysmal supraventricular tachycardia?

The treatment of choice for a hemodynamically stable patient with paroxysmal supraventricular tachycardia (SVT) is adenosine. Adenosine works quickly by temporarily blocking the conduction of electrical impulses through the atrioventricular (AV) node, which helps to restore normal heart rhythm rapidly. This action is particularly effective in terminating episodes of SVT, making it the first-line medication for patients who are stable.

In a hemodynamically stable patient, the rapid administration of adenosine can usually convert the tachycardia back to a normal rhythm, allowing for the relief of symptoms associated with the elevated heart rate. The short half-life of adenosine allows for a quick action, and it is generally well-tolerated.

While other agents, such as beta-blockers and calcium channel blockers, can also play a role in managing SVT—particularly in chronic management or for long-term prevention after initial treatment—they are not typically the first choice for acute conversion. Amiodarone is usually reserved for cases such as ventricular arrhythmias or in patients who are not responsive to other therapies due to its broader effects and longer half-life.

Understanding the pharmacological actions and appropriate indications for these medications